Select Country

 
877-783-6728 (877-StemSave)

StemSave Blog

Low Blood Cell Counts Could Be Treated by Regulating Stem Cells.

Posted by barb@stemsave.com on Dec 16, 2014 11:22:59 AM

Megakaryotes may hold the ability to regulate the amount of blood that stem cells produce.

According to new research from the Stowers Institute for Medical Research, hematopoietic stem cells [stem cells that produce blood] are directly regulated by megakaryocytes, the blood cells responsible for healing wounds. The researchers found that megakaryotes produce two growth factors; one that signals for hematopoietic stem cells to proliferate, and one that keeps them in an inactive state. This relationship controls the amount of blood being produced in the body.

Read More

Topics: Artery, Blood Cancer, stemsaveblog, Metachromatic Leukodystrophy, Debilitating Diseases, Stemcells, autologousstemcells, hematological malignancies, Blood vessel

Stem Cells Immune to Damage from Leukemia Chemotherapy

Posted by artgreco@stemsave.com on Aug 6, 2014 6:09:26 AM

Certain stem cells have been found to be immune to the bone-degenerative side effects of chemotherapy used against leukemia.

A research team, led by Dr. Eric Darling of Brown University, has found a potential source of stem cells to protect children with acute lymphoblastic leukemia against the adverse effects of the chemotherapy drug methotrexate (MTX). Adipose-derived stem cells, which appear to be impervious to the bone-degenerative side effects of MTX, may allow children to undergo the chemotherapy treatment and then regain the lost bone tissue afterwards.

Read More

Topics: Blood Cancer, stemsaveblog, Bone, Debilitating Diseases, Stemcells, Cancer, autologousstemcells, Blood vessel, young stem cells

Stem Cell Treatments for Hematological Malignancies Advance to Clinical Testing Phase

Posted by devin@stemsave.com on Oct 15, 2012 6:30:14 AM

Gamida Cell, a leading adult stem cell therapeutics company has completed enrollment for a Phase I/II trial for hematological malignancies utilizing their NiCord treatment. The treatment is a potential cure for blood cancers, sickle cell disease, thalassemia, severe autoimmune diseases and metabolic diseases. This trial is but one example of the increasing number of stem cell treatments moving out of the lab and entering the clinical testing phase.

Read More

Topics: sickle cell disease, Phase III, Blood Cancer, stemsaveblog, clinical trials, Stemcells, hematological malignancies

AAOMS

AAOMS - American Association of Oral and Maxillofacial Surgeons

 

As the industry leader, StemSave is the only stem cell banking service to be designated as an ASI approved program.

Subscribe to Email Updates

Join our Newsletter

Posts by Topic

see all